ArticleFrontiers in immunology2026
Shared immune dysregulation in systemic lupus erythematosus and colorectal cancer: a multi-omics guided discovery of DNASE1L3-centric efferocytosis deficiency.
Article in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Intestinal and Blood-Brain Barrier Dysfunction in Lupus: Emerging Mechanisms and Modulation by Cinnamon.Molecules (Basel, Switzerland) · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Although immune dysregulation is implicated in both autoimmune diseases and cancer, comparative pathogenesis and immune response mechanisms between systemic lupus erythematosus (SLE) and colorectal cancer (CRC) remain elusive. This study identifies common molecular biomarkers and pathogenic pathways shared between SLE and CRC via multi-omics analysis. Methods: Integrated datasets including SLE (GSE61635, GSE50772, GSE142016) and CRC cohorts (GSE39582, GSE17536, E-MTAB-8107, COAD, READ), were analyzed. Differential expression analysis identified shared genes, and machine learning screened four hub prognostic genes. A risk model based on these genes was constructed to evaluate SLE screening and CRC prognosis. Multi-omics approaches explored mutational profiles, immune infiltration, drug sensitivity, and signaling pathways. Reverse transcription-quantitative polymerase chain reaction (RT-qPCR), staining were performed to confirmed the expression levels of the hub genes. The impact of DNASE1L3 knockdown in the human monocyte cell line THP-1 on phagocytosis of apoptotic intestinal epithelial cell line NCM460 was evaluated using RT-qPCR and flow cytometry. Results: We identified 58 shared differentially expressed genes (DEGs) between SLE and CRC, enriched in apoptosis, oxidative phosphorylation, and immune infiltration. Machine learning highlighted four hub genes ( Conclusion: SLE and CRC exhibit overlapping DEGs, immune profiles, and signaling pathways. The model based on the shared genes-
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.